Search

everythinglearnresearchcommunity

for

Search:↓

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

Finding acceptance of hair loss through psychedelics, and the potential benefits of shrooms. Discussions include sharing experiences with minoxidil, finasteride, nutrafol, laser therapy, micro needling, as well as mental health concerns such as depression, suicidal thoughts, and self-esteem.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.

RU58841 solution developed crystals after refrigeration. Letting it reach room temperature and shaking can dissolve the crystals.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

The conversation is about using a dermastamp for hair loss treatment and concerns about a potentially scam product, pp405. It suggests sticking with known treatments like finasteride and minoxidil.

PP405 targets hair follicle stem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.

PP-405, a potential hair loss treatment, shows promise in stimulating dormant hair follicles and may help with various hair loss types. Current treatments like Minoxidil are still recommended as PP-405 is in early trials and may take years to become available.

The user is questioning if black points on their scalp are new hair follicles. They are using finasteride and minoxidil for hair growth.

PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.

Significant hair regrowth was achieved using EssenGen 6-Plus with 6% minoxidil and 0.05% finasteride, along with Nizoral shampoo, over 12 weeks. No side effects were experienced, highlighting the benefits of a low dose.

The conversation discusses creating a topical catalase solution with phosphate buffered saline, glycerin, and polysorbate 20 for hair loss treatment. The user seeks advice on preparing this solution.

A 35-year-old male uses topical minoxidil, spironolactone, and microneedling for hair loss, with spironolactone prescribed based on a DNA test indicating poor response to finasteride and dutasteride. Despite concerns about the test's validity and spironolactone's side effects, he reports stable or improved hair condition and no low testosterone symptoms.

The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.

The DNA Trichotest is considered unreliable for predicting hair loss treatment responses, and topical spironolactone is questioned for its effectiveness and safety in cis males. Finasteride and Dutasteride are recommended as more reliable treatments for androgenic alopecia.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

Female using Rogaine foam for hair loss had scalp punch biopsy, diagnosed with Androgenetic Alopecia (AGA). Doctor recommended starting Spironolactone 50mg.

The conversation is about a user sharing their positive experience with Scalp Micropigmentation (SMP) for hair loss, highlighting the natural look achieved by a specialized artist. The procedure cost $2600 and was done by Alex Corona in Panama City Beach, FL.

The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.

A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.

Norwood 7 hair loss is often excluded from trials to ensure treatments appear more effective and to reduce costs. Some believe treatments effective for Norwood 5 could work on Norwood 7, but companies prioritize market readiness.

A user wants to make a solution for RU58841 and finasteride powder using only glycerin and asks if ethanol is necessary. They are seeking advice on whether glycerin alone is sufficient.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

PP405 may help with hair regrowth, especially when combined with minoxidil and finasteride, but its long-term effectiveness is unclear. Phase 3 trials are expected to begin soon, with results in a few years.

The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.

The user has been using a hair regrowth regimen for 9-10 months, including topical finasteride and minoxidil, various oils, and supplements like multivitamins and omega-3. They observed fine hairs returning and a change in scalp texture after adding cinnamon oil, questioning if this indicates positive hair regrowth.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.